# Corvus Pharmaceuticals, Inc. (CRVS)

> Source: Nexqual · https://nexqual.com/CRVS · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Corvus Pharmaceuticals, Inc. (CRVS), nexqual.com/CRVS" · informational, not investment advice.

**Price:** USD 10.23 (-2.76% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 10.52 · day 10.18–10.74 · 52w 6.39–26.95 · market cap $861M · NGM

## Key facts
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 33.14 (range 27–42).
- Total return with dividends: 1Y +35.6% vs S&P 500 +14.8%; 5Y +125.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.21, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: CRVS paid no cash dividend in the last five years.
- Short interest: 24.28% of float (as of 2026-10-15), 13.9 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$38.6M | -$32.6M | -$23.4M | -$27.5M | -$43.0M | -$57.0M |
| Net income | -$43.2M | -$41.3M | -$27.0M | -$62.3M | -$15.3M | -$54.1M |
| EPS (diluted) | -$1.03 | -$0.89 | -$0.56 | -$1.02 | -$0.53 | — |
| Free cash flow | -$36.7M | -$27.3M | -$24.0M | — | -$33.0M | -$45.2M |
| Cash + short-term investments | $69.5M | $42.3M | $27.1M | $52.0M | $56.8M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 3.8x · FCF yield -5.26% · Earnings yield -6.29%

## Analysts
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 33.14 (low 27, high 42).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +35.6% | +125.8% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +35.8% | +17.6% |
| Volatility (annualized) | 118.3% | 98.3% |
| Max drawdown | -63.2% (Jan 2026→Oct 2026) | -87.0% (Nov 2021→Mar 2023) |

## Dividends
CRVS paid no cash dividend in the last five years.

## Short interest
17,967,756 shares sold short, 24.28% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 17,180,341 shares (+4.6%). Days to cover: 13.9 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/CRVS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.20 | $-0.19 | −$0.01 | $0 | 4 |
| Next quarter (ends 2026-12-31) | $-0.23 | $-0.21 | −$0.02 | $0 | 4 |
| Current fiscal year (ends 2026-12-31) | $-0.78 | $-0.72 | −$0.06 | $0 | 4 |
| Next fiscal year (ends 2027-12-31) | $-1.07 | $-0.95 | −$0.12 | $4.5M | 4 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±20.8%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 103.5% | ±20.8% |
| 2026-12-18 | 50 | 79.0% | ±26.7% |
| 2027-01-15 | 78 | 96.6% | ±35.3% |
| 2027-04-16 | 169 | 89.5% | ±47.5% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.19 | −$0.17 | Miss −11.8% | — |
| — | Quarter ended Mar 31, 2026 | −$0.15 | −$0.15 | In line | — |
| — | Quarter ended Dec 31, 2025 | −$0.15 | −$0.13 | Miss −15.4% | — |
| — | Quarter ended Sep 30, 2025 | −$0.12 | −$0.13 | Beat +7.7% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).